Targeting of receptor for advanced glycation end products suppresses cyst growth in polycystic kidney disease

Journal of Biological Chemistry

Volumn 289, Issue 13, 2014, Pages 9254-9262

  Park, Eun Young ^a   Kim, Bo Hye ^a   Lee, Eun Ji ^a   Chang, EunSun ^a   Kim, Dae Won ^b   Choi, Soo Young ^b   Park, Jong Hoon ^a  

^a Sookmyung Women's University   (South Korea)

^b Hallym University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALS;

ADVANCED GLYCATION END PRODUCTS; AUTOSOMAL DOMINANTS; BLOOD UREA NITROGENS; DOWN-REGULATION; GENE KNOCK DOWN; POLYCYSTIC KIDNEY DISEASE; RESEARCH GROUPS; THERAPEUTIC TARGETS;

GENES;

ADVANCED GLYCATION END PRODUCT RECEPTOR; CREATININE; SHORT HAIRPIN RNA; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE; PROTEIN KINASE D2;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY MASS; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; MOUSE; NONHUMAN; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL; ADENOVIRIDAE; ANIMAL; CELL LINE; CELL PROLIFERATION; CYSTS; DEFICIENCY; GENETICS; KIDNEY FUNCTION TEST; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SIGNAL TRANSDUCTION;

ADENOVIRIDAE; ANIMALS; CELL LINE; CELL PROLIFERATION; CYSTS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE KNOCKDOWN TECHNIQUES; HUMANS; KIDNEY FUNCTION TESTS; MICE; MOLECULAR TARGETED THERAPY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROTEIN KINASES; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 84897419485     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.514166     Document Type: Article

References (40)

1. Chapin, H. C., and Caplan, M. J. (2010) The cell biology of polycystic kidney disease. J. Cell Biol. 191, 701-710
2. Bello-Reuss, E., Holubec, K., and Rajaraman, S. (2001) Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int. 60, 37-45 (Pubitemid 32587537)
3. Novalic, Z., van der Wal, A. M., Leonhard, W. N., Koehl, G., Breuning, M. H., Geissler, E. K., de Heer, E., and Peters, D. J. (2012) Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J. Am. Soc. Nephrol. 23, 842-853
4. Zafar, I., Ravichandran, K., Belibi, F. A., Doctor, R. B., and Edelstein, C. L. (2010) Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Kidney Int. 78, 754-761
5. Serra, A. L., Poster, D., Kistler, A. D., Krauer, F., Raina, S., Young, J., Rentsch, K. M., Spanaus, K. S., Senn, O., Kristanto, P., Scheffel, H., Weishaupt, D., and Wüthrich, R. P. (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 820-829
6. Walz, G., Budde, K., Mannaa, M., Nürnberger, J., Wanner, C., Sommerer, C., Kunzendorf, U., Banas, B., Hörl, W. H., Obermüller, N., Arns, W., Pavenstädt, H., Gaedeke, J., Büchert, M., May, C., Gschaidmeier, H., Kramer, S., and Eckardt, K. U. (2010) Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 830-840
7. Bukanov, N. O., Smith, L. A., Klinger, K. W., Ledbetter, S. R., and Ibraghimov-Beskrovnaya, O. (2006) Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 444, 949-952 (Pubitemid 46025010)
8. Takiar, V., Nishio, S., Seo-Mayer, P., King, J. D., Jr., Li, H., Zhang, L., Karihaloo, A., Hallows, K. R., Somlo, S., and Caplan, M. J. (2011) Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc. Natl. Acad. Sci. U.S.A. 108, 2462-2467
9. Natoli, T. A., Smith, L. A., Rogers, K. A., Wang, B., Komarnitsky, S., Budman, Y., Belenky, A., Bukanov, N. O., Dackowski, W. R., Husson, H., Russo, R. J., Shayman, J. A., Ledbetter, S. R., Leonard, J. P., and Ibraghimov- Beskrovnaya, O. (2010) Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat. Med. 16, 788-792
10. Xia, S., Li, X., Johnson, T., Seidel, C., Wallace, D. P., and Li, R. (2010) Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts. Development 137, 1075-1084
11. Park, E. Y., Seo, M. J., and Park, J. H. (2010) Effects of specific genes activating RAGE on polycystic kidney disease. Am. J. Nephrol. 32, 169-178
12. Bohlender, J. M., Franke, S., Stein, G., and Wolf, G. (2005) Advanced glycation end products and the kidney. Am. J. Physiol. Renal Physiol. 289, F645-F659 (Pubitemid 41324185)
13. Bierhaus, A., Humpert, P. M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., Stern, D. M., and Nawroth, P. P. (2005) Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 83, 876-886 (Pubitemid 41598688)
14. Busch, M., Franke, S., Rüster, C., and Wolf, G. (2010) Advanced glycation end-products and the kidney. Eur. J. Clin. Invest. 40, 742-755
15. Arumugam, T., Simeone, D. M., Schmidt, A. M., and Logsdon, C. D. (2004) S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J. Biol. Chem. 279, 5059-5065 (Pubitemid 38220521)
16. Zhu, P., Ren, M., Yang, C., Hu, Y. X., Ran, J. M., and Yan, L. (2012) Involvement of RAGE, MAPK, and NF-κB pathways in AGEs-induced MMP-9 activation in HaCaT keratinocytes. Exp. Dermatol. 21, 123-129
17. Cohen, M. P., Sharma, K., Jin, Y., Hud, E., Wu, V. Y., Tomaszewski, J., and Ziyadeh, F. N. (1995) Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists: a novel treatment strategy. J. Clin. Invest. 95, 2338-2345
18. Kelly, D. J., Gilbert, R. E., Cox, A. J., Soulis, T., Jerums, G., and Cooper, M. E. (2001) Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J. Am. Soc. Nephrol. 12, 2098-2107 (Pubitemid 32880346)
19. Taguchi, A., Blood, D. C., del Toro, G., Canet, A., Lee, D. C., Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., Hofmann, M. A., Kislinger, T., Ingram, M., Lu, A., Tanaka, H., Hori, O., Ogawa, S., Stern, D. M., and Schmidt, A. M. (2000) Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405, 354-360 (Pubitemid 30337069)
20. Torres, V. E., and Harris, P. C. (2007) Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities. J. Intern. Med. 261, 17-31 (Pubitemid 46046469)
21. Wu, G., D'Agati, V., Cai, Y., Markowitz, G., Park, J. H., Reynolds, D. M., Maeda, Y., Le, T. C., Hou, H., Jr., Kucherlapati, R., Edelmann, W., and Somlo, S. (1998) Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell 93, 177-188 (Pubitemid 28180852)
22. Park, E. Y., Sung, Y. H., Yang, M. H., Noh, J. Y., Park, S. Y., Lee, T. Y., Yook, Y. J., Yoo, K. H., Roh, K. J., Kim, I., Hwang, Y. H., Oh, G. T., Seong, J. K., Ahn, C., Lee, H. W., and Park, J. H. (2009) Cyst formation in kidney via B-Raf signaling in the PKD2 transgenic mice. J. Biol. Chem. 284, 7214-7222
23. Cowley, B. D., Jr., Ricardo, S. D., Nagao, S., and Diamond, J. R. (2001) Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats. Kidney Int. 60, 2087-2096 (Pubitemid 33070452)
24. Wei, F., Karihaloo, A., Yu, Z., Marlier, A., Seth, P., Shibazaki, S., Wang, T., Sukhatme, V. P., Somlo, S., and Cantley, L. G. (2008) Neutrophil gelatinase-associated lipocalin suppresses cyst growth by Pkd1 null cells in vitro and in vivo. Kidney Int. 74, 1310-1318
25. Hardy, S., Kitamura, M., Harris-Stansil, T., Dai, Y., and Phipps, M. L. (1997) Construction of adenovirus vectors through Cre-lox recombination. J. Virol. 71, 1842-1849 (Pubitemid 27078561)
26. Shibazaki, S., Yu, Z., Nishio, S., Tian, X., Thomson, R. B., Mitobe, M., Louvi, A., Velazquez, H., Ishibe, S., Cantley, L. G., Igarashi, P., and Somlo, S. (2008) Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum. Mol. Genet. 17, 1505-1516 (Pubitemid 351737156)
27. Lu, W., Peissel, B., Babakhanlou, H., Pavlova, A., Geng, L., Fan, X., Larson, C., Brent, G., and Zhou, J. (1997) Perinatal lethality with kidney and pancreas defects in mice with a targeted Pkd1 mutation. Nat. Genet. 17, 179-181
28. Ishihara, K., Tsutsumi, K., Kawane, S., Nakajima, M., and Kasaoka, T. (2003) The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett. 550, 107-113 (Pubitemid 37281366)
29. Lotze, M. T., and Tracey, K. J. (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5, 331-342 (Pubitemid 40516158)
30. Chung, A. C., Zhang, H., Kong, Y. Z., Tan, J. J., Huang, X. R., Kopp, J. B., and Lan, H. Y. (2010) Advanced glycation end products induce tubular CTGF via TGF-β-independent Smad3 signaling. J. Am. Soc. Nephrol. 21, 249-260
31. Torres, V. E., and Harris, P. C. (2006) Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases. Nat. Clin. Pract. Nephrol. 2, 40-55; quiz 55
32. Omori, S., Hida, M., Fujita, H., Takahashi, H., Tanimura, S., Kohno, M., and Awazu, M. (2006) Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J. Am. Soc. Nephrol. 17, 1604-1614 (Pubitemid 43794663)
33. Riehl, A., Németh, J., Angel, P., and Hess, J. (2009) The receptor RAGE: bridging inflammation and cancer. Cell Commun. Signal. 7, 12
34. Xu, N., Glockner, J. F., Rossetti, S., Babovich-Vuksanovic, D., Harris, P. C., and Torres, V. E. (2006) Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis. J. Nephrol. 19, 529-534 (Pubitemid 44823212)
35. Li, X., Magenheimer, B. S., Xia, S., Johnson, T., Wallace, D. P., Calvet, J. P., and Li, R. (2008) A tumor necrosis factor-α-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat. Med. 14, 863-868
36. Guo, J., Ananthakrishnan, R., Qu, W., Lu, Y., Reiniger, N., Zeng, S., Ma, W., Rosario, R., Yan, S. F., Ramasamy, R., D'Agati, V., and Schmidt, A. M. (2008) RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J. Am. Soc. Nephrol. 19, 961-972
37. D'Agati, V., Yan, S. F., Ramasamy, R., and Schmidt, A. M. (2010) RAGE, glomerulosclerosis and proteinuria: roles in podocytes and endothelial cells. Trends Endocrinol. Metab. 21, 50-56
38. Giannini, C., D'Adamo, E., de Giorgis, T., Chiavaroli, V., Verrotti, A., Chiarelli, F., and Mohn, A. (2012) The possible role of esRAGE and sRAGE in the natural history of diabetic nephropathy in childhood. Pediatr. Nephrol. 27, 269-275
39. Forbes, J. M., Thorpe, S. R., Thallas-Bonke, V., Pete, J., Thomas, M. C., Deemer, E. R., Bassal, S., El-Osta, A., Long, D. M., Panagiotopoulos, S., Jerums, G., Osicka, T. M., and Cooper, M. E. (2005) Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 16, 2363-2372 (Pubitemid 41725054)
40. Sourris, K. C., Morley, A. L., Koitka, A., Samuel, P., Coughlan, M. T., Penfold, S. A., Thomas, M. C., Bierhaus, A., Nawroth, P. P., Yamamoto, H., Allen, T. J., Walther, T., Hussain, T., Cooper, M. E., and Forbes, J. M. (2010) Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor. Diabetologia 53, 2442-2451